Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular Dystrophy

Next Previous
X
Search
Trial Profile

A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular Dystrophy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sevasemten (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Acronyms ARCH
  • Sponsors Edgewise Therapeutics

    • Most Recent Events

    • 01 Oct 2024 According to an Edgewise Therapeutics media release, the study will be presented at the 29th International Annual Congress of the World Muscle Society (WMS). The conference will take place at The Prague Congress Centre in Prague, Czechia, October 8-12, 2024.
    • 18 Apr 2024 Results (n=12) assessing Effects of EDG-5506, a Fast Myosin Modulator, on Function and Biomarkers of Muscle Damage in Adults with Becker Muscular Dystrophy presented at the 76th Annual Meeting of the American Academy of Neurology 2024
    • 15 Apr 2024 According to Edgewise Therapeutics Media Release, data from this study will be presented at the American Academy of Neurology 2024 Annual Meeting Podium Presentation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top